文献速递肿瘤 PET/CT骨显像与常规 SPECT

以组织病理学为参考标准评估[18F]AlF-Thretide PET/CT对新诊断前列腺癌患者的诊断效能

Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
PubMed 文献 · J Nucl Med · 2024-07-01

这项前瞻性研究纳入49例活检证实的前列腺癌患者,采用PRIMARY试验评分系统分析[18F]AlF-thretide PET/CT图像,并以病理为参考标准。结果显示患者水平前列腺内肿瘤检出率为93.9%,病灶水平灵敏度58.2%、阳性预测值90.5%;延迟显像较标准显像可检出更多病灶且SUVmax与靶本比更高。

要点

  • 49例新诊断前列腺癌患者中46例(93.9%)前列腺内肿瘤在[18F]AlF-thretide PET/CT上显示病理性摄取。
  • 病灶水平灵敏度58.2%、阳性预测值90.5%,延迟显像较标准显像检出更多病灶(57 vs 49,P=0.005)。
  • 对前列腺内全部病灶及临床显著前列腺癌的检出率,[18F]AlF-thretide PET/CT高于多参数MRI。

核心结论

  • [18F]AlF-thretide PET/CT对原发性前列腺癌患者显示出较高的诊断价值,可作为前列腺癌患者术前评估的优良影像学方法。

研究设计与样本

  • 前瞻性研究纳入49例活检证实的前列腺癌患者,均行[18F]AlF-thretide PET/CT,并采用PRIMARY试验评分系统分析图像。
  • 对3例患者进行[18F]AlF-thretide的剂量学评估;以病理检查为参考标准评估肿瘤位置、数量、大小和Gleason评分,并与PET/CT结果比较。
  • 通过免疫组化染色评估PSMA表达。

主要发现

  • 全部患者均耐受[18F]AlF-thretide PET/CT良好,[18F]AlF-thretide总有效剂量为1.16E-02 mSv/MBq。
  • 患者水平分析中,49例中46例(93.9%)前列腺内肿瘤在[18F]AlF-thretide PET/CT上显示病理性摄取。
  • 病灶水平分析中,[18F]AlF-thretide PET/CT对前列腺内肿瘤的灵敏度和阳性预测值分别为58.2%和90.5%。
  • 延迟显像较标准显像可检出更多病灶(n=57 vs n=49,P=0.005),且延迟显像SUVmax和靶本比均高于标准显像(SUVmax:14.5±16.7 vs 11.4±13.6,P<0.001;靶本比:37.1±42.3 vs 23.1±27.4,P<0.001)。
  • 受试者工作特征曲线分析显示,PRIMARY评分预测真阳性与假阳性病灶的曲线下面积显著高于标准显像SUVmax(P=0.015),并似乎高于延迟显像SUVmax(P=0.257)。

关键数值与推荐

  • 采用PRIMARY试验评分系统对[18F]AlF-thretide PET/CT图像进行分析。
  • 以病理检查为参考标准,评估肿瘤位置、数量、大小和Gleason评分。
  • 通过免疫组化染色评估PSMA表达。
  • 患者水平前列腺内肿瘤病理性摄取率为93.9%(46/49)。
  • 病灶水平灵敏度58.2%、阳性预测值90.5%;[18F]AlF-thretide总有效剂量1.16E-02 mSv/MBq。

临床怎么用

  • 作者认为[18F]AlF-thretide PET/CT对原发性前列腺癌患者具有较高诊断价值,可作为前列腺癌患者术前评估的优良影像学方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to assess the diagnostic value of [18F]AlF-thretide PET/CT in patients with newly diagnosed prostate cancer (PCa). Methods: In total, 49 patients with biopsy-proven PCa were enrolled in this prospective study. All patients underwent [18F]AlF-thretide PET/CT, and the scoring system of the PRIMARY trial was used for PET image analysis. The dosimetry evaluation of [18F]AlF-thretide was performed on 3 patients. Pathologic examination was used as the reference standard to evaluate the location, number, size, and Gleason score of tumors, for comparison with the [18F]AlF-thretide PET/CT results. PSMA expression was evaluated by immunohistochemical staining. Results: All patients tolerated the [18F]AlF-thretide PET/CT well. The total effective dose of [18F]AlF-thretide was 1.16E-02 mSv/MBq. For patient-based analysis of intraprostatic tumors, 46 of 49 (93.9%) patients showed pathologic uptake on [18F]AlF-thretide PET/CT. For lesion-based analysis of intraprostatic tumors, the sensitivity and positive predictive value for [18F]AlF-thretide PET/CT were 58.2% and 90.5%, respectively. Delayed images can detect more lesions than standard images (n = 57 vs. 49, P = 0.005), and the SUVmax and tumor-to-background ratio of the former were higher than those of the latter (SUVmax: 14.5 ± 16.7 vs. 11.4 ± 13.6, P < 0.001; tumor-to-background ratio: 37.1 ± 42.3 vs. 23.1 ± 27.4, P < 0.001). The receiver-operating-characteristic curve analysis showed that the areas under the curve for PRIMARY score-predicted true-positive and false-positive lesions were significantly higher than those for the SUVmax of standard images (P = 0.015) and seemed higher than those for the SUVmax of delayed images (P = 0.257). [18F]AlF-thretide PET/CT showed a higher detection rate than multiparametric MRI for all intraprostatic foci (53.5% vs. 40.8%, P = 0.012) and clinically significant PCa (75.0% vs. 61.4%, P = 0.031). Conclusion: [18F]AlF-thretide PET/CT showed high diagnostic value for patients with primary PCa and can be used as an excellent imaging modality for preoperative evaluation of PCa patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zang J, Yang Y, Chen S, et al. Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard. J Nucl Med. 2024. PMID: 38724276. doi:10.2967/jnumed.123.266940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。